Recent advances and developments in COVID‐19 in the context of allergic diseases
Abstract Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute r...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-09-01
|
| Series: | Clinical and Translational Allergy |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/clt2.12065 |
| _version_ | 1818669407657787392 |
|---|---|
| author | Mei Ding Xiang Dong Yuan‐li Sun Milena Sokolowska Mübeccel Akdis Willem van deVeen Ahmet Kursat Azkur Dilek Azkur Cezmi A. Akdis Ya‐dong Gao |
| author_facet | Mei Ding Xiang Dong Yuan‐li Sun Milena Sokolowska Mübeccel Akdis Willem van deVeen Ahmet Kursat Azkur Dilek Azkur Cezmi A. Akdis Ya‐dong Gao |
| author_sort | Mei Ding |
| collection | DOAJ |
| description | Abstract Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma. Methods Based on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed. Results and Conclusions In this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines. |
| first_indexed | 2024-12-17T06:51:44Z |
| format | Article |
| id | doaj.art-8eb3afceea0f4ba3ab8ffd23f317f594 |
| institution | Directory Open Access Journal |
| issn | 2045-7022 |
| language | English |
| last_indexed | 2024-12-17T06:51:44Z |
| publishDate | 2021-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Allergy |
| spelling | doaj.art-8eb3afceea0f4ba3ab8ffd23f317f5942022-12-21T21:59:35ZengWileyClinical and Translational Allergy2045-70222021-09-01117n/an/a10.1002/clt2.12065Recent advances and developments in COVID‐19 in the context of allergic diseasesMei Ding0Xiang Dong1Yuan‐li Sun2Milena Sokolowska3Mübeccel Akdis4Willem van deVeen5Ahmet Kursat Azkur6Dilek Azkur7Cezmi A. Akdis8Ya‐dong Gao9Department of Allergology Zhongnan Hospital of Wuhan University Wuhan ChinaDepartment of Allergology Zhongnan Hospital of Wuhan University Wuhan ChinaDepartment of Allergology Zhongnan Hospital of Wuhan University Wuhan ChinaSwiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Davos SwitzerlandSwiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Davos SwitzerlandSwiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Davos SwitzerlandDepartment of Virology Faculty of Veterinary Medicine University of Kirikkale Kirikkale TurkeyDivision of Pediatric Allergy and Immunology Department of Pediatrics Faculty of Medicine University of Kirikkale Kirikkale TurkeySwiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Davos SwitzerlandDepartment of Allergology Zhongnan Hospital of Wuhan University Wuhan ChinaAbstract Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma. Methods Based on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed. Results and Conclusions In this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.https://doi.org/10.1002/clt2.12065Schlüsselwörter: AllergieCOVID‐19ImpfungMechanismenTherapie |
| spellingShingle | Mei Ding Xiang Dong Yuan‐li Sun Milena Sokolowska Mübeccel Akdis Willem van deVeen Ahmet Kursat Azkur Dilek Azkur Cezmi A. Akdis Ya‐dong Gao Recent advances and developments in COVID‐19 in the context of allergic diseases Clinical and Translational Allergy Schlüsselwörter: Allergie COVID‐19 Impfung Mechanismen Therapie |
| title | Recent advances and developments in COVID‐19 in the context of allergic diseases |
| title_full | Recent advances and developments in COVID‐19 in the context of allergic diseases |
| title_fullStr | Recent advances and developments in COVID‐19 in the context of allergic diseases |
| title_full_unstemmed | Recent advances and developments in COVID‐19 in the context of allergic diseases |
| title_short | Recent advances and developments in COVID‐19 in the context of allergic diseases |
| title_sort | recent advances and developments in covid 19 in the context of allergic diseases |
| topic | Schlüsselwörter: Allergie COVID‐19 Impfung Mechanismen Therapie |
| url | https://doi.org/10.1002/clt2.12065 |
| work_keys_str_mv | AT meiding recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases AT xiangdong recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases AT yuanlisun recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases AT milenasokolowska recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases AT mubeccelakdis recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases AT willemvandeveen recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases AT ahmetkursatazkur recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases AT dilekazkur recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases AT cezmiaakdis recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases AT yadonggao recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases |